Showing results (421-430 of 480) with videos related to
Sort By:
Pageof 48
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 1, 2015
Risk of Acute Liver Failure in Patients With Drug-Induced Liver Injury: Evaluation of Hy's Law and a New Prognostic ModelVincent Lo Re, Kevin Haynes, Kimberly A Forde, et al.Journal of Viral Hepatitis|July 25, 2023
Prevalence and determinants of hepatitis delta virus infection among HIV/hepatitis B-coinfected adults in care in the United StatesNicole D Ferrante, Michael J Kallan, Sophia Sukkestad, et al.Liver International : Official Journal of the International Association for the Study of the Liver|September 24, 2017
Long-term follow-up of clinical trial patients treated for chronic HCV infection with daclatasvir-based regimensK Rajender Reddy, Stanislas Pol, Paul J Thuluvath, et al.Plos One|January 4, 2014
Profiles of serum cytokines in acute drug-induced liver injury and their prognostic significanceNury M Steuerwald, David M Foureau, H James Norton, et al.Hepatology (Baltimore, Md.)|October 15, 2014
Concordance of sustained virological response 4, 12, and 24 weeks post-treatment with sofosbuvir-containing regimens for hepatitis C virusEric M Yoshida, Mark S Sulkowski, Edward J Gane, et al.The American Journal of Gastroenterology|October 10, 2020
Low Predictability of Readmissions and Death Using Machine Learning in CirrhosisChang Hu, Vikram Anjur, Krishnakant Saboo, et al.Annals of Internal Medicine|November 10, 2015
Sofosbuvir Plus Velpatasvir Combination Therapy for Treatment-Experienced Patients With Genotype 1 or 3 Hepatitis C Virus Infection: A Randomized TrialStephen Pianko, Steven L Flamm, Mitchell L Shiffman, et al.BMJ Open Diabetes Research & Care|September 8, 2017
Postauthorization safety study of the DPP-4 inhibitor saxagliptin: a large-scale multinational family of cohort studies of five outcomesVincent Lo Re, Dena M Carbonari, M Elle Saine, et al.Open Forum Infectious Diseases|August 19, 2015
Predicting Risk of End-Stage Liver Disease in Antiretroviral-Treated Human Immunodeficiency Virus/Hepatitis C Virus-Coinfected PatientsVincent Lo Re, Michael J Kallan, Janet P Tate, et al.Journal of Hepatology|August 12, 2018
No impact of resistance-associated substitutions on the efficacy of sofosbuvir, velpatasvir, and voxilaprevir for 12 weeks in HCV DAA-experienced patientsChristoph Sarrazin, Curtis L Cooper, Michael P Manns, et al.Pageof 48